PT217, an investigational DLL3/CD47 bispecific antibody, remains under first-in-human study for neuroendocrine cancers

Early HumanInvestigationalNot addressed

PT217 (peluntamig), an investigational bispecific antibody targeting DLL3 and CD47 developed by Phanes Therapeutics, is under study in the first-in-human, open-label, dose-escalation/dose-expansion SKYBRIDGE trial (ClinicalTrials.gov NCT05652686) in adults with advanced, DLL3-expressing neuroendocrine carcinomas — including small cell lung cancer, large cell neuroendocrine carcinoma of the lung, and extrapulmonary neuroendocrine carcinoma, a category that includes neuroendocrine prostate cancer. No peer-reviewed clinical results exist for PT217 as of this review — results are not yet available, and this record makes no treatment-effect claim of any kind. The sponsor, via its own press releases (not an FDA-published record), has stated that the FDA granted Fast Track Designation for two separate indications (extensive-stage small cell lung cancer, and metastatic neuroendocrine prostate cancer); this is presented here as a reported sponsor claim requiring direct regulatory corroboration before being treated as regulatory fact, not as a confirmed FDA action — and even if confirmed, this designation would expedite development and review, not constitute an approval or a claim that the drug works. This is deliberately a trial-status story, not a results story: it should never be described as effective, as working, or as a treatment option, since no such evidence currently exists in the public record. Fast Track designation claims here are sourced only to sponsor company press releases, since the FDA does not independently publish a searchable list of individual Fast Track grants — a genuine, structural sourcing limitation, not a specific red flag about this drug.

What This Means

PT217 (peluntamig), an investigational bispecific antibody targeting DLL3 and CD47, is being tested in an ongoing, open-label, first-in-human, Phase 1/2 trial (SKYBRIDGE), primarily to establish safety and an appropriate dose across multiple cohorts. NO PEER-REVIEWED CLINICAL RESULTS EXIST for PT217 as of this review — results are not yet available, and no treatment-effect claim of any kind is made or should be inferred here. The sponsor (not the FDA directly) has stated, via its own press releases, that the FDA granted Fast Track Designation for two indications (extensive-stage small cell lung cancer, and metastatic neuroendocrine prostate cancer). This is presented as a REPORTED SPONSOR CLAIM, not as confirmed regulatory fact — it requires direct corroboration against an FDA-published record before it should be treated as established, and a Fast Track Designation, even if confirmed, is a development/review-timeline designation, never an efficacy claim or approval.

What This Doesn't Mean

This is not evidence the drug works — no peer-reviewed human efficacy or safety result exists yet, and the only public trial-design reference found was a "Trial in Progress" conference abstract describing the study's design, not its results. This must never be described as effective, as working, or as a treatment option. The Fast Track claim above must not be presented as an FDA-confirmed fact — it is a sponsor statement pending direct regulatory corroboration, and even a confirmed Fast Track Designation would not itself establish safety or efficacy.

Why It Matters

Represents continued investment in DLL3-targeted, dual-mechanism (bispecific antibody) approaches to neuroendocrine cancers — a group of cancers, including neuroendocrine prostate cancer, with historically few targeted treatment options — worth tracking as the trial progresses.

Promise & Proof

Proof — strength of the evidence 2 / 5

Base score from evidence stage: Early Human.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
An early-stage finding (preclinical or early human) that already shows at least one concrete signal of significance above.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with advanced, DLL3-expressing neuroendocrine carcinomas, including small cell lung cancer, large cell neuroendocrine carcinoma of the lung, and extrapulmonary neuroendocrine carcinoma (a category including neuroendocrine prostate cancer), enrolled in a first-in-human, open-label, dose-escalation/dose-expansion trial (SKYBRIDGE, NCT05652686). A reported target enrollment of approximately 203 patients was not independently confirmed against the trial registry itself in this research pass. (Adults)

This is a trial-status story, not a results story, and must remain strictly Phase 1/2 investigational framing. No peer-reviewed clinical efficacy or safety data currently exists in the public record for this drug — do not infer either from the trial's existence or from the sponsor-reported Fast Track claim. The Fast Track designation claim is sourced only to sponsor company press releases and is explicitly NOT presented as FDA-confirmed regulatory fact in this record — it requires direct corroboration against an FDA-published record (e.g. via openFDA or a direct fda.gov retrieval, not a press release) before any future revision of this record may state it as confirmed. Registry status (recruiting/enrollment/cohort structure) is time-sensitive and should be re-checked before publication, not assumed static.

Full evidence details

Study design: Non-randomized trial

Funding & Conflicts

Sponsor: Phanes Therapeutics.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

SKYBRIDGE trial registry (first-in-human study of PT217/peluntamig) (opens in a new tab) (Clinical-trial registry) NCT05652686 Load-bearing source NCT05652686
SKYBRIDGE trial registry (first-in-human study of PT217/peluntamig). NCT05652686.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13